|Bid||72.17 x 700|
|Ask||72.40 x 200|
|Day's range||72.12 - 72.62|
|52-week range||63.76 - 86.27|
|PE ratio (TTM)||7.87|
|Earnings date||5 Feb 2018 - 9 Feb 2018|
|Forward dividend & yield||2.08 (2.87%)|
|1y target est||84.90|
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
Gilead Sciences (GILD) is trending lower today, along with biotech in general, after Argus downgraded the stock. Analyst David Toung cut his rating on Gilead from Buy to Hold, citing concerns about increasing R&D spending at a time when sales from its blockbuster franchise is waning. Toung writes that he's concerned about the steepening decline of its hepatitis C products, as well as "flattening" HIV sales, which account for some 68% of the company's revenues.
Jim Cramer zipped through his take on callers' favorite stocks, including that of a smaller oil exploration company.
Shares of Gilead Sciences (GILD) have been on a steady downward slide since it hit a 52-week high in early September. Add to that, some investors remain unconvinced that Gilead didn’t overpay when it bought Kite Pharma for $12 billion. What do investors think of this deal and where are we?
Gilead Sciences’ (GILD) revenue rose 31% in 2015 before falling 7% in 2016. Revenue from the United States, Europe, Japan, and other countries drove revenue growth in 2015. US and…
Less than a month ago, Evercore ISI analyst Josh Schimmer upgraded Bluebird bio (BLUE) to an Outperform and raised his price target to $152 a share. Today, Schimmer returned to the sidelines on the gene therapy company. As of Friday’s closing bell, Bluebird had closed at $156.25 a share, well above Schimmer’’s previous price target.
Is GlaxoSmithKline (GSK) about to throw down with Gilead Sciences (GILD) over a new HIV drug? RBC Capital Markets analyst Brain Abrahams says that recent patent portfolio activity by Glaxo suggests that the British drug maker may be preparing to initiate a lawsuit claiming that Gilead’s experimental HIV drug bictegravir infringes on its patents.
Gilead Sciences (GILD.O) and GlaxoSmithKline (GSK.L) are heading for an HIV showdown, pushing rival treatment visions and competing products that are expected to hit the market in the next few months. Gilead is likely to secure the bigger near-term win, as it builds on a 20-year-old strategy of combining three drugs to control the AIDS virus, while GSK is placing a longer bet that its core drug is potent enough to work with just one other. Gilead says the idea may risk drug resistance because the virus will only have to evade two drugs rather than three.
PharmaNet developed the first drug for hepatitis C, Sofosbuvir, sold with brand name Sovaldi. Gilead bought the small company for several billion dollars and immediately raised the price of the required ...
Juno Therapeutics may still have an advantage that allows it to win market share in what's becoming a competitive market for CAR-T medicine.
In 3Q17, Gilead Sciences’ (GILD) Viread generated revenues of $274 million, a ~10% fall YoY (year-over-year) and a ~9% fall QoQ (quarter-over-quarter).
In 3Q17, Gilead Sciences’ (GILD) Harvoni generated revenues of $973 million, a ~48% fall YoY (year-over-year) and a ~30% fall QoQ (quarter-over-quarter).
In 3Q17, Gilead Sciences’ (GILD) Atripla generated revenues of $439 million, a ~5% fall YoY. In the US and European markets, its revenues were $324 million and $79 million, respectively.
In 3Q17, Gilead Sciences (GILD) generated revenues of $6.5 billion, which reflected a ~13% fall YoY (year-over-year) and a ~9% fall QoQ (quarter-over-quarter).
Biotech stocks toppled last week following disappointing results from the likes of Celgene and Gilead, an analyst said Monday.